(From left) Professor Lu Aiping, Professor Rick Wong and Ms Cheng Cheung-ling sign the cooperation framework agreements on behalf of the two parties


(左起)呂愛平教授、黃偉國教授與鄭翔玲女士代表雙方簽署兩份合作框架協議

Date: 13 Jul 2015 (Monday)

Archive

School of Chinese Medicine signs cooperation framework agreements with Mainland pharmaceutical company

中醫藥學院與內地製藥企業簽署合作框架協議

The School of Chinese Medicine (SCM) and the Beijing Tide Pharmaceutical Company Limited (Tide) signed two cooperation framework agreements on 8 July, setting the way forward for collaborations in drug discovery and consolidation in the use of healthcare data to foster public health and wellness.
   
The signing of the agreements by Professor Lu Aiping, Dean of SCM, and Ms Cheng Cheung-ling, Managing Director of Tide, was witnessed by Professor Rick Wong, Acting President and Vice-Chancellor, Dr Zhang Ge, Associate Director of the Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ) and the Institute of Integrated Bioinformedicine and Translational Science (IBTS) of SCM, and Miss Theresa Tse, Executive Director and Chairman of the Board of Directors of Sino Biopharmaceutical Limited, the parent company of Tide.

Professor Rick Wong said that Tide, the first high-technology pharmaceutical company in the Chinese mainland to develop, manufacture and sell targeted drugs, shares the same mission of improving human health as SCM. He looked forward to the discovery of innovative drugs in the near future through collaborations between the two parties.

Under the agreements, TMBJ and IBTS under the School of Chinese Medicine will embark on a number of collaborations with Tide. The collaborations between TMBJ and Tide will focus on the discovery of new drugs to treat chronic inflammatory diseases, autoimmune diseases, malignant tumours, and bone and joint diseases as well as the development of new drug delivery systems. The two parties will also join hands to nurture postgraduate and postdoctoral researchers, and set up a research and development centre devoted to the creation of new models of drug discovery. In addition, IBTS will collaborate with Tide on the integration and development of healthcare data related to chronic diseases, refractory diseases and malignant tumours.

中醫藥學院與北京泰德製藥股份有限公司於7月8日簽署兩份合作框架協議,奠定雙方今後聯合研發創新藥物,以及整合和開發利用健康管理數據的方向,致力提升大眾健康。

雙方代表中醫藥學院院長呂愛平教授與泰德製藥董事長鄭翔玲女士,在署理校長黃偉國教授、骨與關節疾病轉化醫學研究所及整合生物信息醫學與轉化科學研究所副主任張戈博士,以及泰德母公司中國生物製藥有限公司執行董事暨董事會主席謝其潤小姐的見證下簽署兩份協議。

黃偉國教授表示,泰德製藥是內地第一家研發、生產和銷售系列靶向藥物的高科技製藥企業,其宗旨與中醫藥學院改善大眾健康的目標一致。他期望雙方的合作能讓創新藥物的研發工作早日結出成果。

根據協議,中醫藥學院轄下的骨與關節疾病轉化醫學研究所及整合生物信息醫學與轉化科學研究所將與泰德製藥開展一系列的合作,其中骨與關節疾病轉化醫學研究所與泰德製藥的合作重點圍繞慢性炎症疾病、自身免疫疾病、惡性腫瘤、骨與關節疾病,以及新型藥物遞送系統等範疇的創新藥物研發,並將攜手培訓研究生和博士後,建立聯合研發中心,逐步建設具國際領先水平的創新藥物研發新模式。另一方面,整合生物信息醫學與轉化科學研究所與泰德製藥的合作則以慢性病、難治性疾病、惡性腫瘤等為重點,開展健康大數據的整合與開發。